Anti Cell Proliferative

ASX
LCT 0.018   Last updated EOD 16th September 2019
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

Anti Cell Proliferative

NO FURTHER INVESTMENT IN THIS TARGET

Target: Glioma

 

Gliomas are the most common primary brain tumour, making up 81 percent of malignant brain tumours. Although relatively rare, they are highly malignant. Glioblastoma, the most common glioma, has a 5-year relative survival of less than 5 percent. There is currently no cure.

 

Working with Sir Richard Faull’s Centre for Brain Research, we evaluated compounds that prevent human glioma cells from proliferating in vitro.

 

At this point, our due diligence identified that this is a difficult target. Consequently, we decided not to invest further in this project.

PRINT PAGE print-icon
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.